Chief Executive Officer Appointment
Brisbane, Nov 14, 2018 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to announce that it has appointed Mr Steven Lydeamore as Chief Executive Officer (CEO), effective as of 3rd December 2018.
Anatara's Chair, Sue MacLeman welcomed the appointment of Mr Lydeamore as a key step in the Company's development and transition to its focus on human health.
Commenting on the appointment, Ms MacLeman said, "We are very fortunate to have attracted someone of Steven's calibre to lead Anatara at this important stage of the Company's journey. Steve has demonstrated through his previous roles that he has the ability to successfully commercialise products on a global scale, driving growth and shareholder value. He has a deep understanding of the human health space and brings a strong track record of success in sales and marketing; research and development, business development, mergers and acquisitions, manufacturing and finance spanning Asia Pacific, Europe, Latin America and North America and will be key in leading the next phase of Anatara's growth".
"On behalf of the Board, I would also like to thank Dr Tracie Ramsdale, who has been serving as Interim CEO since May 2018. Tracie will revert to her previous role of Non-Executive Director upon Steve's commencement."
Mr Lydeamore has 26 years' international experience in the pharmaceutical industry, working in Australia, USA and Canada. His experience extends to sales and marketing; research and development, business development, mergers and acquisitions, manufacturing and finance, including involvement in the commercial development of numerous consumer products. He spent 11 years working for Canada's largest pharmaceutical company, Apotex Inc, in a variety of roles including Vice President Global Business Development, Chief Business Officer and Managing Director of Apotex International Inc, during which time net sales grew by 42% to >$550 million. His most recent role with Apotex was as President of Apobiologix, a subsidiary responsible for development manufacturing and global commercialization of biosimilars, where he was responsible for more than 150 employees and net sales of $100 million.
He returned to Australia in August 2017 to take up the role of Chief Financial Officer for Bionomics Ltd. Prior to Apotex, Mr Lydeamore worked in various finance roles for F.H. Faulding & Co. Limited in Australia over a ten year period followed by four years in the United States at Mayne Pharma (USA) Limited as Vice President Corporate and Business Development. Mr Lydeamore holds a Bachelor of Business (Applied Economics) (Deakin) and a Master of Business Administration (RMIT). He is a member of CPA Australia; Australian Institute of Company Directors and Licensing Executives Society (U.S.A and Canada), Inc.
Mr Lydeamore said, "I am delighted to join Anatara. With strong intellectual property and a talented and passionate team, Anatara has a solid base for building a valuable business in the area of gastrointestinal health".
To view the release, please visit:
http://abnnewswire.net/lnk/40SIX2A2
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
